Caliper's Q4 Sales Rise 29 Percent But Xenogen Buy Swells Losses | GenomeWeb
NEW YORK (GenomeWeb News) — Caliper Life Sciences today said fourth-quarter revenues increased 29 percent as R&D spending was up 34 percent and losses surged 500 percent.
Total receipts for the three months ended Dec. 31, 2006, increased to $34.7 million from $26.9 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.